Travere Therapeutics (TVTX) Interest Expenses (2011 - 2026)

Travere Therapeutics has reported Interest Expenses for 8 years, with the latest figure at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses fell 19.5% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $10.1 million (down 10.14% YoY), and the FY2025 full-year result was $10.7 million, down 4.31% from the prior year.
• Interest Expenses for Q1 2026 stood at $2.3 million, up from $2.2 million in the prior quarter.
• The five-year high for Interest Expenses was $2.9 million in Q1 2025, with the low at $2.2 million in Q4 2025.
• Historically, Interest Expenses has averaged $2.7 million across 4 years, with a median of $2.8 million in 2023.
• Annual changes were most pronounced in 2025 — Interest Expenses rose 2.04% — and 2026, when it retreated 19.5%.
• Travere Therapeutics' Interest Expenses stood at $2.8 million in 2023, then declined by 1.83% to $2.8 million in 2024, then retreated by 19.19% to $2.2 million in 2025, then advanced by 2.31% to $2.3 million in 2026.
• The last three Interest Expenses figures came in at $2.3 million (Q1 2026), $2.2 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.